Sort   by:  
 Page size 
UnknownPB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL
Not available
S-EPMC9431483 | biostudies-literature
ProteomicsEpigenetic silencing of tight junction protein CLDN10B in renal cancer including post-transplantation RCC and its endogenous reactivation by CRISPR results in cell growth suppression.
Background The kidney's tubular system, composed of nephrons and collecting ducts, relies on cellular planar polarity and tight junctions to maintain structure and function. Disruptions in this polarity contribute to diseases like cystic kidney disease and cancer. Tight junctions, such as those form...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2024-10-01 | MSV000095998 | MassIVE
UnknownTIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial.
Not available
S-EPMC11815413 | biostudies-literature
ProteomicsPhase I study of immunopeptidome-guided personalized multi-peptide vaccines in chronic lymphocytic leukemia patients under BTK-inhibitor-based regimes
Cancer peptide vaccines hold promise as therapeutic approach, but their effectiveness has been hampered by lack of suitable antigens and the variability of HLA backgrounds among patients, which restricts their applicability.. We here introduce a novel warehouse concept for the construction of person...
ORGANISM(S): Homo sapiens (Human) 
2026-01-22 | PXD059004 | Pride
Human Cll Immunopeptidomics Lc-ms/ms 
ProteomicsThe oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKAC...
ORGANISM(S): Homo sapiens (Human) 
2022-10-13 | PXD029882 | Pride
Cancer Hla ligands Mass spectrometry Fibrolamellar hepatocellular carcinoma Immunopeptidomics Fl-hcc 
UnknownT<sub>SCM</sub>-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial.
Not available
S-EPMC12644732 | biostudies-literature
TranscriptomicsBulk RNA-seq of primary visceral adipocytes isolated from wildtype mice or mice with adipocyte specific deletion of Atg7
Genes involved in the autophagic pathway are risk factors for the development of inflammatory bowel disease. In addition, patients with Crohn’s disease exhibit a profound expansion of mesenteric fat during the pathology. We investigated in our study the role of autophagy in mature adipocyte during i...
ORGANISM(S): Mus musculus 
2023-01-14 | E-MTAB-12498 | biostudies-arrayexpress
UnknownIntegrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Not available
S-EPMC7449872 | biostudies-literature
UnknownAdipocyte autophagy limits gut inflammation by controlling oxylipin-IL10
Not available
S-SCDT-10_15252-EMBJ_2022112202 | biostudies-other
TranscriptomicsMitochondrial carrier SLC25A34 links clock, diet, and temperature control of adipocyte lipid cycling
BAT transcriptome from control and brown adipocyte-specific Rev-erbα/β double knockout mice housed at thermoneutrality or cold-challenged for 6 hours. Brown adipose tissue (BAT) samples were collected from control and brown adipocyte-specific Rev-erbα/β double knockout mice (Ucp1-Cre; Nr1d1/2 fl/fl)...
ORGANISM(S): Mus musculus 
2026-09-23 | E-MTAB-17580 | biostudies-arrayexpress
Sort   by:  
 Page size